Printed sensors for research and development on antiviral drugs
Within this project, cellasys is responsible for the specification and characterization of the sensors. Currently, the growth behavior of living cells can be monitored electronically on the graphene structures using the IMOLA-Technology. To achieve this goal the scientists have developed a new graphene ink and have optimized the printing process. Stability and biocompatibility of the microstructures were both confirmed during the initial phase of the project starting in 2014.
cellasys’ BioChips have been used primarily in medical research. With these new advances in printing technology, they can now be manufactured at considerably lower costs. Thus, they are now suitable for industrial applications such as pharmaceutical research and development of drugs to combat viral infections. Additionally, applications in the field of comprehensive water monitoring are now conceivable. The projected completion date of this collaborative research project is in 2017, ending with a parallelization of the measurement setup and a final testing.
Further information: http://www.graphene-biosensors.eu
This research and development project is partially funded by the Innovate UK and the German Federal Ministry of Education and Research (BMBF) within the Framework Concept "Research for Tomorrow's Production" (funding number 02PN2240) and managed by the Project Management Agency Karlsruhe (PTKA).
cellasys GmbH offers system solutions for microphysiometry. These include services such as contract research, research & development, and production & maintenance. Furthermore cellasys works as consultants for development of applications, data analysis and data interpretation. The microphysiometric systems monitor different parameters directly from living cells. These parameters include extracellular acidification (pH), cellular respiration (pO2) and morphology (impedance). The measurements are label-free, parallel, continuous and in real-time. With the BioChip technology you can e.g. determine the efficiency of a drug outside of humans (or animals) prior to the start of the therapy.
Further information: http://www.cellasys.com